Mustang Bio Announces FDA Acceptance Of IND Application For MB-109, A Novel Combination Of MB-101 And MB-108, For The Treatment Of Recurrent Glioblastoma And High-Grade Astrocytoma
Portfolio Pulse from Benzinga Newsdesk
Mustang Bio, Inc. (NASDAQ:MBIO) has announced that the FDA has accepted the company's Investigational New Drug (IND) application for MB-109, a combination of MB-101 and MB-108, for the treatment of recurrent glioblastoma and high-grade astrocytoma. The Phase 1 study will assess the safety, tolerability, and efficacy of MB-109 and is expected to begin enrolling patients in 2024.
October 26, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mustang Bio's IND application for MB-109 has been accepted by the FDA, which could potentially lead to a new treatment option for recurrent glioblastoma and high-grade astrocytoma. This is likely to have a positive impact on the company's stock in the short term.
The FDA's acceptance of Mustang Bio's IND application for MB-109 is a significant regulatory milestone for the company. This could potentially lead to a new treatment option for recurrent glioblastoma and high-grade astrocytoma, which would likely increase the company's market share and revenue in the future. As such, this news is expected to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100